NCI-2023-00610

A Phase 1, First-in-Human, Dose-Finding and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Activity of XmAb�808 in Combination with Pembrolizumab in Selected Advanced Solid Tumors

A Phase 1 study, which is the first of its kind in humans, is being conducted to find the appropriate dose and expand the investigation of XmAb®808 when used alongside Pembrolizumab, an immunotherapy medicine, in specific advanced solid tumors. The study aims to assess the safety, tolerance, how the body processes the drugs, and their effectiveness in treating these types of cancers.

Phase 1 study: First step in testing a new medicine in people, and tests if treatment is safe, determines the right dose, and checks for any side effects.

For more information about the trial, click the link below:

https://clinicaltrials.gov/ct2/show/NCT05585034

Clinical Trial Site: Columbia

To see all available clinical trials click here.